This is what analysts have to say about Balchem Corporation (NASDAQ:BCPC) after last week.

January 6, 2018 - By Kurt Siggers

 This is what analysts have to say about Balchem Corporation (NASDAQ:BCPC) after last week.
Investors sentiment increased to 1.58 in Q3 2017. Its up 0.44, from 1.14 in 2017Q2. It improved, as 16 investors sold Balchem Corporation shares while 39 reduced holdings. 18 funds opened positions while 69 raised stakes. 27.53 million shares or 3.97% more from 26.48 million shares in 2017Q2 were reported.
Aperio Gp Llc holds 0% or 9,507 shares. Svcs Of America reported 1.74% of its portfolio in Balchem Corporation (NASDAQ:BCPC). Company Retail Bank reported 5,945 shares or 0.01% of all its holdings. Fifth Third Bankshares holds 0% in Balchem Corporation (NASDAQ:BCPC) or 2,377 shares. California Employees Retirement System invested in 78,600 shares. Aviance Capital Mngmt Lc holds 107 shares or 0% of its portfolio. California-based California State Teachers Retirement has invested 0.01% in Balchem Corporation (NASDAQ:BCPC). Teacher Retirement Sys Of Texas owns 2,635 shares or 0% of their US portfolio. Deutsche Fincl Bank Ag reported 0% of its portfolio in Balchem Corporation (NASDAQ:BCPC). 533,894 are held by Conestoga Advisors Limited Co. Strs Ohio has 79,400 shares for 0.03% of their portfolio. Riverhead Cap Mngmt has invested 0.01% in Balchem Corporation (NASDAQ:BCPC). Barclays Pcl holds 2,584 shares. Summit Creek has invested 1.51% in Balchem Corporation (NASDAQ:BCPC). Group holds 25,126 shares.

Balchem Corporation (NASDAQ:BCPC) Ratings Coverage

Among 2 analysts covering Balchem (NASDAQ:BCPC), 0 have Buy rating, 1 Sell and 1 Hold. Therefore 0 are positive. Balchem had 3 analyst reports since March 8, 2016 according to SRatingsIntel. The stock of Balchem Corporation (NASDAQ:BCPC) has “Sell” rating given on Friday, November 4 by Pivotal Research. On Tuesday, March 8 the stock rating was downgraded by Sidoti to “Neutral”. The rating was maintained by Pivotal Research on Friday, August 4 with “Sell”. Below is a list of Balchem Corporation (NASDAQ:BCPC) latest ratings and price target changes.

04/08/2017 Broker: Pivotal Research Rating: Sell New Target: $60.0000 Maintain

The stock increased 0.11% or $0.09 during the last trading session, reaching $80.45. About 173,629 shares traded or 101.83% up from the average. Balchem Corporation (NASDAQ:BCPC) has risen 37.77% since January 6, 2017 and is uptrending. It has outperformed by 21.07% the S&P500.

Balchem Corporation develops, manufactures, and markets specialty performance ingredients and products for the food, nutritional, feed, pharmaceutical, and medical sterilization industries in the United States and internationally. The company has market cap of $2.58 billion. The companyÂ’s Human Nutrition & Health segment offers creamer systems, dairy replacers, powdered fats, nutritional beverage bases, beverages, juice and dairy bases, chocolate systems, ice cream bases and variegates, cereals, grain based snacks, and cereal based ingredients; microencapsulation solutions; and human grade choline nutrients and mineral amino acid chelated products for wellness applications. It has a 40.63 P/E ratio. The Company’s Animal Nutrition & Health segment provides microencapsulated products that enhance health and milk production in ruminant animals; chelation technology, which provides enhanced nutrient absorption for species; and choline chloride, an essential nutrient for monogastric animal health.

More recent Balchem Corporation (NASDAQ:BCPC) news were published by: Globenewswire.com which released: “Balchem Corporation Acquires Innovative Food Processors, Inc.” on June 02, 2017. Also Streetinsider.com published the news titled: “Form 8-K BALCHEM CORP For: Dec 13” on December 19, 2017. Nasdaq.com‘s news article titled: “Balchem Corporation (BCPC) Ex-Dividend Date Scheduled for December 26, 2017” with publication date: December 22, 2017 was also an interesting one.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.